Loading viewer...
earnings
Format: PDF earnings
Five Prime Therapeutics' second quarter 2016 earnings presentation dated August 4, 2016. The biotech company presents its oncology-focused pipeline including clinical candidates Cabiralizumab (FPA008), FPA144, and FP-1039 across multiple tumor indications.
24 Pages
Xylem Inc.